Subcutaneous vs Intramuscular vs Intranasal: Understanding Peptide Administration Routes

Small molecule drugs are typically designed to survive oral administration — they are lipophilic enough to cross gut epithelium, resistant to stomach acid, and metabolically stable through first-pass hepatic metabolism. Research peptides generally lack these properties: they are cleaved by stomach proteinases, are too polar to cross gut epithelium efficiently, and are extensively metabolized in the liver.

This means the default administration route for oral bioavailability (which works for most pharmaceuticals) fails for most research peptides. Alternative routes — subcutaneous injection, intramuscular injection, intranasal delivery — each bypass different parts of the oral bioavailability problem.

Oral bioavailability (the fraction of an administered compound that reaches systemic circulation intact — typically 60 to 90% for lipophilic small molecules, but often less than 1% for most peptides given orally) varies dramatically by route. Understanding this variation is essential for interpreting published peptide research and designing appropriate protocols.

Subcutaneous injection (administration into the subcutaneous tissue between the skin and the muscle — the loose connective tissue and fat layer) is the most common administration route in published peptide research. Subcutaneous tissue is highly vascular with a rich capillary network that absorbs compounds through direct diffusion into the bloodstream.

Bioavailability from subcutaneous administration for most peptides exceeds 80 to 90% — close to intravenous. The primary difference from IV is the rate of absorption rather than the total amount absorbed: subcutaneous administration produces a slower, sustained blood concentration curve rather than the rapid peak of IV injection. This slower absorption may be pharmacologically advantageous for some endpoints.

Published research using subcutaneous administration for BPC-157, TB-500, GHK-Cu, MOTS-c, and SS-31 represents the majority of the preclinical literature for these compounds. When reviewing dose data from published studies, subcutaneous route should be assumed unless otherwise specified, and dose extrapolations to other routes should account for bioavailability differences.

Intramuscular injection (administration directly into muscle tissue — typically the deltoid, vastus lateralis, or gluteal muscles) achieves bioavailability comparable to subcutaneous for most peptides but with a different absorption rate. Muscle tissue has higher blood flow than subcutaneous fat, producing faster absorption and an earlier, higher peak blood concentration.

For most research peptides, the choice between intramuscular and subcutaneous administration is primarily one of convenience and personal preference rather than significant pharmacokinetic difference. Both routes produce high bioavailability. The faster absorption from intramuscular injection may matter for compounds where peak concentration drives the pharmacological effect, but for most peptides studied for tissue repair or systemic effects, the difference is not clinically meaningful.

Published peptide research using intramuscular administration is less common than subcutaneous in the preclinical literature, but both routes appear in human-adjacent research. Researchers should match the administration route to the published protocol they are using as a reference whenever possible.

Intranasal administration exploits a unique anatomical feature: the olfactory epithelium in the nasal cavity directly contacts the olfactory bulb of the brain through tiny channels in the cribriform plate. Compounds absorbed through this pathway can reach cerebrospinal fluid (the clear fluid that bathes the brain and spinal cord) and brain tissue directly, bypassing the blood brain barrier that prevents most compounds from reaching central nervous system targets.

This transcribform plate pathway (the route of passage from nasal cavity to olfactory bulb through perforations in the cribriform plate bone — a direct physical connection between nasal epithelium and brain tissue) is the mechanistic basis for intranasal delivery of CNS-targeted peptides. Semax and Selank are both administered intranasally in published Russian clinical research specifically because their targets are central nervous system receptors.

The bioavailability of intranasal peptides for CNS effects depends on the fraction absorbed through the olfactory pathway versus conventional nasal mucosal absorption into systemic circulation. Published data shows measurable CNS drug concentrations after intranasal peptide administration that exceed what would be predicted from systemic absorption alone, supporting the direct CNS delivery hypothesis.

Most peptides are not orally bioavailable for systemic effects. However, two special cases exist in the research catalog: compounds targeting the GI tract specifically (where local activity in the gut does not require systemic absorption) and very small peptides that resist enzymatic degradation.

BPC-157 is a documented special case: published research demonstrates efficacy in both injectable and intragastric (oral) administration routes in animal models, particularly for GI-targeted endpoints. The proposed explanation is that BPC-157 retains some activity even under the degradative conditions of the stomach and intestine — possibly due to its gastric juice origin and consequent design for activity in that environment.

KPV, as a tripeptide, is small enough to resist rapid proteolytic degradation and has published oral bioavailability data in GI inflammation models. These exceptions do not generalize to larger peptides, and researchers should not assume oral bioavailability for compounds other than those with specific published evidence supporting it.

Reconstitution of lyophilized peptides for injectable administration requires bacteriostatic water or sterile water for injection, not tap water or standard drinking water. The reconstitution solvent should be sterile to prevent contamination of the reconstituted compound.

Injection site rotation (administering successive injections at different anatomical locations rather than the same site repeatedly) is standard practice in all injectable research protocols to prevent local tissue irritation and lipohypertrophy (fatty tissue buildup at frequently injected sites — a documented effect of repeated subcutaneous injections at the same location).

Storage of reconstituted peptides differs from lyophilized storage: reconstituted peptides in aqueous solution are vulnerable to degradation and should be stored at 4°C and used within 1 to 4 weeks depending on the specific compound. Lyophilized peptides stored properly at −20°C have a significantly longer shelf life. Researchers should follow published storage recommendations for each specific compound rather than applying generic peptide storage rules.

Researchers reviewing administration route considerations for specific compounds can find detailed product information and research guides at Blackwell BioLabs. All compounds ship lyophilized with batch specific COA documentation confirming purity and identity.